Introduction
============

Genes promoting overall youthfulness in the form of delayed aging have been reported in the centenarian population ([@bib22]; [@bib5]; [@bib3]; [@bib27]), but whether these genes also promote skin youthfulness (SY) is unclear. In fact, genes that promote SY have, to date, not been identified. Multiple sources have estimated that over US\$140 billion yearly is spent on cosmetics worldwide ([@bib21]), testifying to the intense and broad interest in promoting SY. Anecdotally, some centenarians possess facial skin that appears decades younger than their chronologic age. This dissociation between phenotypic and chronologic age may be a unique window to examine whether particular genotypes associate with SY.

Prior skin aging studies have categorized skin aging parameters into intrinsic versus extrinsic characteristics, believed to reflect genetic versus environmental factors contributing to skin aging features, respectively (e.g., [@bib11]; [@bib30]). However, data suggest that extrinsic skin aging parameters can have a strong genetic basis. For instance, *MC1R* gene mutations can promote severe photoaging ([@bib9]). Heritability analyses in twins have shown that extrinsic skin aging parameters such "sun damage" exhibit 60% heritability ([@bib13]). Recently, extrinsic skin aging parameters of facial photoaging have been linked to a genetic change, a single-nucleotide polymorphism (SNP) in the intronic area of the *STXBP5L* gene, in a genome-wide association study of French women ([@bib16]). Hence, this study aims to examine skin aging in a global sense, and includes both intrinsic and extrinsic skin aging parameters, both of which have genetic underpinnings.

The primary objective of this study was to assess whether there may be genes that confer SY in a unique centenarian population, by identifying individuals that lack global skin aging features (both intrinsic and extrinsic as both have a genetic basis) compared with individuals of similar chronologic age. The secondary objective of this study was to determine whether *SY* genes overlap with longevity genes in this centenarian population.

Results
=======

Cases and controls for facial SY phenotype were identified using a global skin aging score (SAS) incorporating intrinsic and extrinsic skin aging parameters ([@bib12]). The average difference between chronologic age and SAS (i.e., CA minus SAS), or average "delta," for the entire discovery group was 15.5. To avoid bias in assigning SY cases and controls for the genome-wide association study (GWAS), individuals whose "deltas" were greater than the average "delta" were defined as cases (individuals with SY), and those whose "deltas" were less than or equal to the group average were defined as controls (individuals without SY). There were no individuals whose "delta" equaled the group average.

The global SASs were determined by a board-certified dermatologist experienced in assessing skin aging parameters (see Materials and Methods section). Bland--Altman analysis showed the differences in skin aging ratings at two time points ([Supplementary Figure S1 online](#sup1){ref-type="supplementary-material"}). The rating differences at two time points that fell outside the 95th percentile were distributed across the range of average skin ages, indicating lack of bias in rating for any particular skin age ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} online).

Clinical characteristics of the case and control groups are reported in [Table 1](#tbl1){ref-type="table"}. Linear regression adjusted for age, gender, and personal or family history of centenarians. There were no significant differences in smoking history, body mass index, or personal history of skin cancer between cases and controls. All female subjects in the discovery group were postmenopausal.

A conventional genome-wide association study on an Ashkenazi Jewish discovery group (*n*=428) was performed using Affymetrix 6.0 SNP Array. SNP quality controls included removal of 22,118 SNPs that were not in Hardy--Weinberg equilibrium, with 901,470 SNPs remaining for analysis. Eigenstrat method showed no stratification, with good homogeneity between cases and controls ([Supplementary Figure S2 online](#sup1){ref-type="supplementary-material"}). Isolation-by-distance studies in this Jewish diaspora were reported previously ([@bib4]; [@bib15]). Identity-by-descent analysis showed that all individuals in the discovery group were unrelated ([Supplementary Figure S3 online](#sup1){ref-type="supplementary-material"}). Quantile--quantile plots of the *P*-values are shown in [Supplementary Figure S4](#sup1){ref-type="supplementary-material"} online.

Six SNPs met the Bonferroni threshold with *P*~allele~\<10^−8^; two of these six had *P*~genotype~\<10^−8^ ([Table 2a](#tbl2){ref-type="table"}). A Manhattan plot of the discovery group is shown in [Figure 1](#fig1){ref-type="fig"}. Quantitative trait loci mapping confirmed linkage disequilibrium ([Figure 2](#fig2){ref-type="fig"}).

To explore the effects of the asymmetry in percent of centenarians between SY cases and SY controls in the discovery group, we corrected for this and report the effect on the *P*~alleles~ for each of the six SNPs [Supplementary Table S1 online](#sup1){ref-type="supplementary-material"}. These *P*-values remain significant when the asymmetry is corrected for.

A gene network to assess coexpression of the six significant SNPs identified in the discovery group is shown in [Supplementary Figure S5 online](#sup1){ref-type="supplementary-material"}. The six SNPs form four clusters of coexpression but no physical interaction.

To confirm these findings of the discovery group, the six candidate SNPs were interrogated by MassARRAY in a replication group (*n*=436). Clinical characteristics of the case and control groups of the replication group are reported in [Supplementary Table S2a online](#sup1){ref-type="supplementary-material"}. After covariate correction for age and gender, the significance of rs6975107 was confirmed. This SNP is located in the intronic region of *KCND2* (potassium voltage-gated channel, Shal-related family member 2) (*P*~genotype~=0.023).

The six candidate SNPs were interrogated by MassARRAY in a second replication group (*n*=371). Clinical characteristics of the case and control groups of the second replication group are reported in [Supplementary Table S2B online](#sup1){ref-type="supplementary-material"}. After covariate correction for age and gender, the significance of rs318125 and rs7616661 were confirmed ([Tables 2b and c](#tbl2){ref-type="table"}). The SNP rs318125 is downstream of *DIAPH2* (diaphanous homolog 2 (*Drosophila*)) (*P*~allele~=0.010, *P*~genotype~=0.002). The SNP rs7616661 is downstream of *EDEM1* (ER degradation enhancer, mannosidase α-like 1) (*P*~genotype~=0.042).

An alternative method to analyze the X-chromosome SNPs identified from the discovery group would be to assume a dominant mode instead of correcting for gender. Using the dominant mode, only one out of three of the X-linked SNPs, rs5916727, was significant (*P*~dominant~=4.70 × 10^−8^) in the discovery group. None of the three X-linked SNPs were confirmed in the two replication groups using this dominant mode analysis.

As it is not known whether *KCND2* is expressed in human skin, we performed immunohistochemistry for *KCND2* in older adult human facial skin. Double immunofluorescence staining with anti-*KCND2* and an anti-Langerin antibody confirmed that *KCND2* is located on Langerhans cells (LCs) in human facial epidermis ([Figure 3](#fig3){ref-type="fig"}). *DIAPH2* has been associated with human premature ovarian ([@bib6]; [@bib18], [@bib19]), although it is not reported to be significantly expressed in human skin. *EDEM1* is expressed in human skin and is associated with endoplasmic reticulum--associated degradation of glycoproteins ([@bib26]).

In case X-chromosome--associated SNPs could be missed using the genotypic mode for association analysis, the *P*-values for genotypic mode when females alone are included in the groups are reported in [Supplementary Table S3 online](#sup1){ref-type="supplementary-material"}. There were no new significant signals from the X-chromosome SNPs in genotypic mode for either the first or second replication group. However, rs5916727 located in an intronic region of *IL1RAPL2* on the X chromosome (*P*~allele~=0.017) and rs1578826 located in an intronic region of *DACH2* on the X chromosome (*P*~allele~=0.003) did become significant in the second replication group when females alone were included. *IL1RAPL2* has been associated with autism ([@bib23]), a phenotype located in the head region. Gene expression of *DACH2* in humans is unknown, but does appear in the dermatomyotome of embryonic mice head region ([Supplementary Figure S6](#sup1){ref-type="supplementary-material"} online).

Discussion
==========

This study supports the hypothesis that facial SY may be associated with specific genes. In particular, we identify and replicate three genes that may promote human facial SY in an Ashkenazi Jewish population: *KCND2*, *DIAPH1*, and *EDEM1*. Although functional studies may directly confirm the biologic relevance of these three genes in facial SY, the informed consent process in this study did not include the provision for skin biopsies.

Nevertheless, *KCND2*, a voltage-gated potassium channel expressed in LCs, suggests an intriguing potential link of SY to skin immune response. Physiologically, the number of LCs in human skin is known to decrease with age ([@bib28]). Functionally, voltage-gated potassium channels can modulate phagocytic capacity of LCs in mice ([@bib20]) Recently, dendritic cells have been linked to inflammation and age-related diseases ([@bib7]; [@bib14]). A direct link between *KCND2* gene regulation, altered LC function, and subsequent potential effect on skin phenotype remains to be determined.

The possible role of *DIAPH2* in SY is plausible, as defects in *DIAPH2* underlie premature ovarian insufficiency in humans ([@bib6]; [@bib18]). The association of menopause and skin aging has been widely reported ([@bib24]; [@bib10]), although the precise mechanism by which the SNP downstream of *DIAPH2* identified in this study exerts its effect on the SY phenotype is unclear.

*EDEM1* is an intriguing and logical candidate *SY* gene. *EDEM1* associates with lifespan in *Drosophila melanogaster* and *Caenorhabditis elegans* ([@bib17]). *EDEM1* levels are reduced in fibroblasts taken from a dwarf mouse model of longevity, and these fibroblasts are more resistant to cell death from stressors such as UV light ([@bib1]). Future studies on fibroblasts from individuals with and without SY may determine whether *EDEM1* levels are different, and whether this difference confers resistance to cell death from UV light in humans. One could speculate that if the SY phenotype was due to resistance to cell death in fibroblasts, then SY individuals might have more collagen fibers in the dermis than those without SY.

In this initial study, we aimed to broadly control for UV exposures by only including individuals residing in the same location, the New York metropolitan area. Individuals who were immigrants to New York were all from Poland or Ukraine with similar average UV index as New York metropolitan area. Current studies are ongoing in which detailed UV exposure histories are being collected to more precisely account for this covariate. However, extrinsic factors such as UV exposures have been shown to account for only 10% of the discriminant ability of the skin aging scoring method that we utilized in this study ([@bib12]). Hence, the effect of UV exposures on the phenotypes in this GWAS is not likely to be large.

As this study included a large number of centenarians, it was unclear whether the *SY* genes would overlap with longevity genes, such as *IGF1* ([@bib5]; [@bib2], [@bib3]; [@bib27]; [@bib8]). The candidate *SY* genes in this study do not clearly overlap with known longevity genes in humans. However, *EDEM1* levels appear to be lower in a dwarf mouse model for longevity that also possesses lower levels of IGF1, suggesting a possible connection between *IGF1* and *EDEM1* that merits further study ([@bib1]). Interestingly, a recent GWAS on facial photoaging suggested an association with an SNP in linkage disequilibrium with FBXO40, which can modulate the IGF1 pathway ([@bib16]), a regulator of human longevity and lifespan in animal models ([@bib29]). It is possible that with larger sample size, we might be able to detect additional candidate *SY* genes, especially if more than one SNP contributes to the SY phenotype; SNPs that interact to lead to SY phenotype might not individually reach genome-wide significance with our current sample size.

Finally, studies are underway to examine whether genes that promote SY also protect against age-associated diseases in other organ systems such as diabetes, cancer, and neurologic disease, which can impact human longevity.

Materials and Methods
=====================

Study design and population
---------------------------

This study was performed in accordance with the Declaration of Helsinki Principles, including Institutional Review Board approval at both Albert Einstein College of Medicine and Stanford University School of Medicine. After written informed consent, women and men of Ashkenazi Jewish descent (defined as having four Ashkenazi Jewish grandparents) living in the New York metropolitan area who were are part of the LonGenity Project at Albert Einstein College of Medicine were included in the discovery group for this GWAS. The LonGenity database has been useful in identifying gene variants promoting longevity ([@bib5]; [@bib2], [@bib3]; [@bib27]). Individuals who had immigrated to New York were from Poland or Ukraine with an average UV index from March to September comparable to New York metropolitan area (5.74 vs. 6.34, respectively). Individuals with self-reported history of facial cosmetic procedures or use of topical antiaging medication such as tretinoin at time photographs were taken were excluded from the study. A first replication group was assembled after the discovery group. Several years after, a second replication group was accrued. The study flow is depicted in [Supplementary Figure S7 online](#sup1){ref-type="supplementary-material"}.

Statistical adjustment for covariates
-------------------------------------

Mean ages, gender distribution, centenarian status, mean body mass index, personal history of skin cancer, smoking history, and menopausal status were assessed in the discovery group. Significant differences between SY cases and SY controls were adjusted for by multivariate regression in the GWAS. These covariates were also assessed and adjusted if significantly different in the two replication groups.

Facial skin aging assessments
-----------------------------

Frontal facial photographs were rated for skin aging features by a board-certified dermatologist experienced in assessing skin aging and who was blinded to the chronological ages of the study participants. Whenever possible, the same blue background and 12 megapixel digital camera was used to obtain photographs.

A global SAS to include both intrinsic and extrinsic skin aging parameters was adapted from [@bib12], and applied to all participants in this study ([Supplementary Table S4 online](#sup1){ref-type="supplementary-material"}). To ensure reproducibility, this scale was tested using 300 randomly selected photographs from the study on the dermatologist who eventually rated all the photographs in this study. The same set of photographs was shown to the dermatologist rater after a 2-week interval. Intrarater reproducibility and potential bias across a range of SASs was assessed by Bland--Altman analysis ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"} online).

To assess whether a GWAS restricted to an intrinsic aging parameter might be informative, we analyzed the correlation between an intrinsic aging feature (fine wrinkling) and an extrinsic aging parameter (coarse wrinkling). Using a four-point severity scale, fine wrinkles and coarse wrinkles were rated on 300 individuals of various chronologic ages in this study by the dermatologist rater who rated all the participants in this study. The Spearman\'s rank-order correlation test showed a significant correlation between the two scores at 0.43, *P*\<0.0001, 95% confidence interval: 0.33--0.52. Hence, patients with higher fine wrinkle scores also had higher coarse wrinkle scores, and a GWAS with fine wrinkling alone was not performed.

Definition of SY cases and SY controls were as described in Results section. Examples of individuals with and without SY are shown in [Supplementary Figure S8 online](#sup1){ref-type="supplementary-material"}.

Methods of genotyping and quality control
-----------------------------------------

Genotypes for the discovery group were generated from peripheral blood DNA processed with Affymetrix 6.0 SNP Array (Affymetrix, Santa Clara, CA) to interrogate 906,000 SNPs. SNPs with more than 10 missing calls were removed from the analysis. SNPs that were not in Hardy--Weinberg equilibrium (using PLINK software) were also removed from the analysis. In total, 901,470 SNPs remained for analysis. GWAS was performed using JMP Genomics and SAS software (Cary, NC). Genome-wide statistical significance utilized the Bonferroni threshold at *P*\<10^−8^. *P*-values were plotted as a quantile--quantile plot ([Supplementary Figure S4 online](#sup1){ref-type="supplementary-material"}). Manhattan plot was generated to examine the distribution of significant SNPs across all chromosomes ([Figure 1](#fig1){ref-type="fig"}). Quantitative trait locus analysis was performed to confirm linkage disequilibrium ([Figure 2](#fig2){ref-type="fig"}).

Targeted interrogation of candidate SNPs in the replication groups was performed using MassARRAY system (Sequenom, San Diego, CA). After adjustment for covariates as described above, *χ*^2^ analysis was performed on the candidate SNPs between cases and controls using a significance threshold *P*\<0.05.

Assessment for population stratification
----------------------------------------

Principal component analysis plots of all the participants in the discovery group were used to assess for population stratification by Eigensoft package (version 2.0). ([Supplementary Figure S2 online](#sup1){ref-type="supplementary-material"}).

Additional quality controls
---------------------------

Isolation-by-distance studies have been previously reported for the subjects in this study ([@bib4]; [@bib15]). The impact of isolation by distance does not apply to this study population as they are an Ashkenazi Jewish diaspora in the New York metropolitan area. This population has been shown to be genetically distinct but still more similar to other Jews such as European Jews and Sephardic Jews than non-Jews ([@bib15]).

Identity-by-descent analysis among all possible pairs of individuals in the discovery group was performed ([Supplementary Figure S4 online](#sup1){ref-type="supplementary-material"}). Values below 0.125 (second-degree cousins) were considered unrelated. All individuals in the discovery group were unrelated.

Gene associations, gene expression, and gene networks
-----------------------------------------------------

The UCSC genome browser (<http://genome.ucsc.edu>), dbSNP (single-nucleotide polymorphism database) (<http://www.ncbi.nlm.nih.gov/projects/SNP>), and GeneCards version 3 were used to search the candidate SNPs for gene associations and gene expression in human skin. Gene Paint (<http://www.genepaint.org>) was used to search gene expression patterns in mice and humans. GeneMANIA (http://geneMANIA.org) was used to search for gene interactions in the most significant SNPs.

Immunohistochemistry
--------------------

To assess the gene expression of *KCND2* in human skin, immunohistochemistry was performed using 1:50 dilution of both rabbit anti-*KCND2* (Sigma; HPA029068; St Louis, MO) and mouse anti-Langerin (Dendritics; clone 306G9; Waltham, MA) antibodies on methanol-fixed-frozen facial skin of an older individual. S100 (Dako; Z0311; Carpenteria, CA)-positive control staining was performed at 1:400 dilution. The tissue was visualized with confocal microscopy acquired on a Leica SP2 AOBS Laser Scanning Microscope with an HCX PL APO × 63 oil immersion objective. Images were arranged with ImageJ (Solms, Germany), Adobe Photoshop (San Jose, CA), and Adobe Illustrator (San Jose, CA).

*In situ* hybridization
-----------------------

Template for *DACH2* mRNA for *in situ* hybridization was amplified from embryonic mouse cDNA by PCR using sequence-specific primers that included the promoter sites for T3 or T7 RNA polymerase. *DACH2* antisense riboprobe was transcribed with T7 RNA polymerase in the presence of Dig-11-UTP (Roche, Indianapolis, IN). Section *in situ* hybridizations were performed by incubating tissue sections in hybridization buffer (Ambion Corporation, Austin, TX) at 70 °C for 12 hours, followed by the addition of riboprobe (approximate concentration of 0.2--0.3 μg ml probe per kilobase of probe complexity). Nonspecifically bound probe was removed with high stringency washes (0.1°---SSC, 65 °C). For color detection, embryos or slides were blocked with 10% sheep serum, 1% Boehringer--Mannheim Blocking Reagent (Roche) and levamisole, and developed using nitro blue tetrazolium chloride (Roche) and 5-bromo-4-chloro-3-indolyl phosphate (Roche). After developing, the slides were coverslipped with aqueous mounting medium ([Supplementary Figure S6 online](#sup1){ref-type="supplementary-material"}).
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###### 

Click here for additional data file.

![**Manhattan plot shows that single-nucleotide polymorphisms (SNPs) are distributed across all chromosomes in the discovery group with significant SNPs labeled.** Results are plotted as negative log~10~-transformed *P*-values from a genotypic association test using allele mode. Significant SNPs are shown in [Table 2](#tbl2){ref-type="table"}.](jid2013381f1){#fig1}

![**Quantitative trait loci analysis for candidate skin youthfulness (*SY*) genes identified in discovery group.** *y*-Axis shows negative transformed log~10~ of significant *P*~alleles~.](jid2013381f2){#fig2}

![***KCND2* stains Langerhans cells (LCs) in facial skin of an older adult individual.** (**a**) Confocal microscopy of skin immunostained with anti-*KCND2* antibody (green) shows positivity in three cells in the epidermis (original magnification, × 63). (**b**) Same section of skin with positive staining of the same three cells in the epidermis using anti-Langerin antibody (red). (**c**) Red and green fluorescence in the same three cells in epidermis, confirming *KCND2* stains LCs. (**d**) S100-positive control. Bar=100 μm.](jid2013381f3){#fig3}

###### Characteristics of cases (SY group) and controls (no-SY group) in the discovery group (*n*=428)

  **Characteristic**                             **[Cases: SY]{.ul}** **Delta\>avg. delta**   **[Controls: no-SY]{.ul}** **Delta⩽avg. delta**   ***P*-value**
  ---------------------------------------------- -------------------------------------------- ------------------------------------------------- ---------------
  *N*                                            218                                          210                                                
  Chronologic age, mean in years±SD              79.3**±**15.4                                93.3**±**10.4                                     \<0.0001
  Delta SY, mean±SD                              24.6**±**6.6                                 6.7**±**6.7                                       \<0.0001
  Female (%)                                     67%                                          70%                                               0.43
  Body mass index (kg m^−2^), mean**±**SD        24.4**±**4.03                                23.6**±**4.34                                     0.48
  \% With no family history of centenarians      65%                                          16%                                               \<0.0001
  Positive smoking history (%)                   25%                                          37%                                               0.85
  Positive personal history of skin cancer (%)   13%                                          18%                                               0.32

Abbreviations: GWAS, genome-wide association study; SAS, skin aging score; SY, skin youthfulness.

Cases and controls were identified using a global SAS incorporating intrinsic and extrinsic skin aging parameters. The average difference between CA and SAS (that is, CA minus SAS), or average "delta," for the entire discovery group was 15.5. To avoid bias in assigning SY cases and SY controls for the GWAS, individuals whose "deltas" were greater than the average "delta" were defined cases (individuals with SY), and those whose "deltas" were less than or equal to the group average were defined as cases (individuals without SY). There were no individuals whose "delta" equaled the group average. *P*-values are calculated by Fisher\'s exact test or *t*-test to assess for significant differences overall between cases and controls. Examples of SY cases and SY controls are shown in [Supplementary Figure S8](#sup1){ref-type="supplementary-material"} online.

###### Significant SNPs identified in the discovery group, and results of the first and second replication groups

  **dbSNP**                         **Chromosome**  **Physical position**    **Gene relationship**  **Gene distance**     **Gene**    **BP change**      **Prob allele**        **Prob genotype**
  -------------------------------- ---------------- ----------------------- ----------------------- ------------------- ------------ --------------- ----------------------- -----------------------
  *(A) Discovery group*                                                                                                                                                      
   Rs6975107                              7         120,168,143                     Intron          0                     *KCND2*        C−\> T       **4.15 × 10**^**−9**^   **3.74 × 10**^**−9**^
   Rs318125                               X         97,090,551                    Downstream        348,298               *DIAPH2*       C−\> T         **4.35 × 10^−9^**         1.25 × 10^−5^
   Rs5916727                              X         104,294,270                     Intron          0                    *IL1RAPL2*      C−\> T         **6.66 × 10^−9^**         1.34 × 10^−5^
   Rs11863929                             16        86,861,934                     Upstream         159,445               *ZNF469*       C−\> G         **1.77 × 10^−8^**         5.48 × 10^−7^
   Rs1578826                              X         85,889,112                      Intron          0                     *DACH2*        T−\> C         **2.20 × 10^−8^**         5.46 × 10^−6^
   Rs7616661                              3         5,940,543                     Downstream        703,894               *EDEM1*        T−\> G         **4.82 × 10^−8^**       **3.37 × 10^−8^**
  *(B) First replication group*                                                                                                                                              
   Rs6975107                              7         120,168,143                     Intron          0                     *KCND2*        C−\> T               0.133                 **0.023**
   Rs318125                               X         97,090,551                    Downstream        348,298               *DIAPH2*       C−\> T               0.332                   0.332
   Rs5916727                              X         104,294,270                     Intron          0                    *IL1RAPL2*      C−\> T               0.623                   0.456
   Rs11863929                             16        86,861,934                     Upstream         159,445               *ZNF469*       C−\> G               0.370                   0.371
   Rs1578826                              X         85,889,112                      Intron          0                     *DACH2*        T−\> C               0.576                   0.245
   Rs7616661                              3         5,940,543                     Downstream        703,894               *EDEM1*        T−\> G               0.390                   0.180
  *(C) Second replication group*                                                                                                                                             
   Rs6975107                              7         120,168,143                     Intron          0                     *KCND2*        C−\> T               0.709                   0.494
   Rs318125                               X         97,090,551                    Downstream        348,298               *DIAPH2*       C−\> T             **0.010**               **0.002**
   Rs5916727                              X         104,294,270                     Intron          0                    *IL1RAPL2*      C−\> T               0.686                   0.347
   Rs11863929                             16        86,861,934                     Upstream         159,445               *ZNF469*       C−\> G               0.344                   0.604
   Rs1578826                              X         85,889,112                      Intron          0                     *DACH2*        T−\> C               0.341                   0.117
   Rs7616661                              3         5,940,543                     Downstream        703,894               *EDEM1*        T−\> G               0.216                 **0.042**

Abbreviations: dbSNP, single-nucleotide polymorphism database; GWAS, genome-wide association study.

\(A\) Results of GWAS on discovery group showing SNPs with a significance level of *P*\<10^−8^, in bold. (B) Results of targeted interrogation of candidate SNPs in first replication group. Significance level is *P*\<0.05, in bold. (C) Results of targeted interrogation of candidate SNPs in a second replication group. Significance level is *P*\<0.05, in bold. Prob allele denotes *P*-value of allele (*P*~allele~) frequency differences between case and control groups; Prob genotype denotes *P*-value of genotype (*P*~genotype~) frequency differences between case and control groups. NA indicates that the SNP was monomorphic (i.e., only one genotype).
